

Fernando Magro

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4836785/fernando-magro-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

245
papers

8,991
citations

40
h-index

90
g-index

285
ext. papers

11,284
ext. citations

3.8
avg, IF

5.82
L-index

#	Paper	IF	Citations
245	DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i132-i134	1.5	
244	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.. <i>Advances in Therapy</i> , 2022 , 1	4.1	1
243	DOP56 Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i103-i105	1.5	
242	DOP87 Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2022 , 16, i129-i130	1.5	
241	Comment on "The Effect of Hyperbaric Oxygen Therapy on Rectal Ulcers after Argon Plasma Coagulation".. <i>GE Portuguese Journal of Gastroenterology</i> , 2022 , 29, 80-81	1.1	
240	Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 , 7, 390-391	18.8	1
239	Clinical efficacy of endoscopic balloon dilation for Crohn's disease strictures.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 , 7, 503	18.8	
238	Composite outcomes in observational studies of Crohn's disease: a systematic review and meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2022 , 15, 175628482210927	4.7	
237	Rectal Perforation by a Balloon Spacer: A Rare Cause of Rectal Perforation Addressed Endoscopically.. <i>GE Portuguese Journal of Gastroenterology</i> , 2021 , 28, 416-419	1.1	1
236	The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1153-1165	4.5	3
235	Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2567-2576.e9	6.9	2
234	ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 879-913	1.5	22
233	Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00320	4.2	3
232	Ileal Crohn's Disease Exhibits Similar Transmural Fibrosis Irrespective of Phenotype. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00330	4.2	0
231	Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 1707-1719	1.5	5
230	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. <i>United European Gastroenterology Journal</i> , 2021 , 9, 451-460	5.3	6
229	Interaction between the Renin-Angiotensin System and Enteric Neurotransmission Contributes to Colonic Dysmotility in the TNBS-Induced Model of Colitis. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5

228	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
227	COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. <i>United European Gastroenterology Journal</i> , 2021 , 9, 750	5.3	2
226	Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2021 , 53, 1571-1579	3.3	0
225	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , 2021 , 20, 102849	13.6	3
224	Aminosalicylates and COVID-19: Facts or Coincidences?. <i>Gastroenterology</i> , 2021 , 160, 1884-1885	13.3	5
223	Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab. <i>BioDrugs</i> , 2021 , 35, 35-45	7.9	0
222	Potassium channels in intestinal epithelial cells and their pharmacological modulation: a systematic review. <i>American Journal of Physiology - Cell Physiology</i> , 2021 , 320, C520-C546	5.4	5
221	European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. <i>United European Gastroenterology Journal</i> , 2021 , 9, 13	5.3	38
220	Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis. <i>Journal of Crohns and Colitis</i> , 2021 , 15, 551-566	1.5	1
219	2,4,6-trinitrobenzenesulfonic acid-induced colitis in <i>Rattus norvegicus</i> : a categorization proposal. <i>Experimental Animals</i> , 2021 , 70, 245-256	1.8	1
218	Short Inflammatory Bowel Disease Questionnaire: translation and validation to the Portuguese language. <i>Health and Quality of Life Outcomes</i> , 2021 , 19, 59	3	2
217	Age at Diagnosis Is Determinant for the Outcome of Inflammatory Bowel Disease: Is It a Myth?. <i>Clinical and Translational Gastroenterology</i> , 2021 , 12, e00309	4.2	0
216	Inflammatory Bowel Disease in Migrant Populations: Should we Look Even Further Back?. <i>Current Drug Targets</i> , 2021 , 22, 1706-1715	3	0
215	Challenges and Opportunities in IBD Clinical Trial Design. <i>Gastroenterology</i> , 2021 , 161, 400-404	13.3	1
214	Epithelial Neutrophilic Infiltrate: The Rising Star in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	0
213	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 857-873	24.2	5
212	Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis.. <i>United European Gastroenterology Journal</i> , 2021 ,	5.3	1
211	Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis.. <i>Scandinavian Journal of Gastroenterology</i> , 2021 , 1-8	2.4	2

210	Genetic Variants of the MGAT5 Gene Are Functionally Implicated in the Modulation of T Cells Glycosylation and Plasma IgG Glycome Composition in Ulcerative Colitis. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00166	4.2	6
209	Microbiota-derived butyrate regulates intestinal inflammation: Focus on inflammatory bowel disease. <i>Pharmacological Research</i> , 2020 , 159, 104947	10.2	35
208	Gut bacterial microbiome composition and statin intake-A systematic review. <i>Pharmacology Research and Perspectives</i> , 2020 , 8, e00601	3.1	8
207	Methylation patterns in dysplasia in inflammatory bowel disease patients. <i>Scandinavian Journal of Gastroenterology</i> , 2020 , 55, 646-655	2.4	4
206	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 1503-1511	1.5	34
205	Prospective study of blood viral load of Epstein-Barr virus, herpes virus type 6 and human parvovirus B19 in Crohn's disease: Does therapy matter?. <i>Journal of Clinical Virology</i> , 2020 , 129, 104515	14.5	
204	Is tofacitinib a game-changing drug for ulcerative colitis?. <i>United European Gastroenterology Journal</i> , 2020 , 8, 755-763	5.3	5
203	DOP13 Clinical and endoscopic response to ustekinumab in Crohn's disease: Week 16 interim analysis of the STARDUST trial. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S049-S052	1.5	4
202	Heterogeneity of endoscopic full-thickness resection scars. <i>Gastrointestinal Endoscopy</i> , 2020 , 92, 433-434	4.2	3
201	Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 1066-1073	1.5	7
200	Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 454-464	18.8	31
199	Comparison of the Nancy Index With Continuous Geboes Score: Histological Remission and Response in Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 1021-1025	1.5	7
198	Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 743-756	1.5	3
197	Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision. <i>Frontiers in Medicine</i> , 2020 , 7, 590527	4.9	3
196	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 4-22	1.5	320
195	Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1054-1069	6.9	18
194	Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1707-1719	4.5	9
193	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 155-168	1.5	122

192	Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure. <i>American Journal of Gastroenterology</i> , 2020 , 115, 179-189	0.7	23
191	Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. <i>Digestive and Liver Disease</i> , 2020 , 52, 138-142	3.3	13
190	Unraveling the Role of ACE2, the Binding Receptor for SARS-CoV-2, in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1787-1795	4.5	10
189	P051 Quantifying inflammation and fibrosis through a surgical histopathological score can differentiate ileal Crohn's disease phenotypes and predict postoperative progressive disease. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S158-S160	1.5	
188	The new simplified MARIA score applies beyond clinical trials: A suitable clinical practice tool for Crohn's disease that parallels a simple endoscopic index and fecal calprotectin. <i>United European Gastroenterology Journal</i> , 2020 , 8, 1208-1216	5.3	4
187	Inflammatory Bowel Disease - Non-biological treatment. <i>Pharmacological Research</i> , 2020 , 160, 105075	10.2	15
186	Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
185	Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by Prevalence. <i>Clinical and Translational Gastroenterology</i> , 2020 , 11, e00227	4.2	1
184	Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide study.. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820923836	4.7	
183	Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S798-S806	1.5	51
182	The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study. <i>United European Gastroenterology Journal</i> , 2020 , 8, 949-960	5.3	5
181	Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820965790	4.7	3
180	Health-Related Quality of Life in Patients with Moderate to Severe Ulcerative Colitis: Surgical Intervention versus Immunomodulatory Therapy. <i>Digestion</i> , 2020 , 101, 631-637	3.6	0
179	Utility of stent double palliation for esophageal cancer with airway involvement: the extremis of care. <i>Ecological Management and Restoration</i> , 2020 , 33,	3	2
178	Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 169-175	1.5	12
177	Sexual Quality of Life in Inflammatory Bowel Disease: A Multicenter, National-Level Study. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 746-755	4.5	8
176	The daily impact of COVID-19 in gastroenterology. <i>United European Gastroenterology Journal</i> , 2020 , 8, 520-527	5.3	24
175	Prevalence, risk factors and global impact of musculoskeletal injuries among endoscopists: a nationwide European study. <i>Endoscopy International Open</i> , 2020 , 8, E470-E480	3	12

174	What forecasting the prevalence of inflammatory bowel disease may tell us about its evolution on a national scale. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819860044	4.7	7
173	Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819869141	4.7	2
172	OP15 Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S009-S010	1.5	1
171	Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 1387-1393	1.5	9
170	P153 Quantum blue anti-adalimumab: development and evaluation of a point of care rapid test for measuring anti-adalimumab antibodies in human serum. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S165-S166	1.5	15
169	Anti-TNF treatment failure: drug levels, immunogenicity, or both?. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 326-327	18.8	0
168	Hospitalization trends of the Inflammatory Bowel Disease landscape: A nationwide overview of 16 years. <i>Digestive and Liver Disease</i> , 2019 , 51, 952-960	3.3	12
167	Accuracy of the new rapid test for monitoring adalimumab levels. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819828238	4.7	9
166	P780 Medical treatment and surgery in patients with elderly-onset inflammatory bowel disease: 3-year follow-up of Epi-IBD 2010-2011 cohorts. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S510-S511	1.5	
165	Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?. <i>Current Medicinal Chemistry</i> , 2019 , 26, 248-258	4.3	3
164	P202 Quantum blue anti-infliximab: development and evaluation of a point of care rapid test for measuring anti-infliximab antibodies in human serum. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S194-S195	1.5	1
163	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1181-1187	6.1	31
162	P740 Sexual quality of life in inflammatory bowel disease: a multi-centre, national-level study. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S491-S491	1.5	
161	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. <i>Digestive Diseases</i> , 2019 , 37, 266-283	3.2	29
160	Delayed Intramural Duodenal Hematoma After a Simple Diagnostic Endoscopic Ultrasonography Fine-Needle Aspiration Procedure. <i>ACG Case Reports Journal</i> , 2019 , 6, e00279	0.6	1
159	P113 Accuracy of a new rapid test assay for monitoring adalimumab levels. <i>Journal of Crohns and Colitis</i> , 2019 , 13, S144-S144	1.5	
158	A Narrative Review on Anti-Tumor Necrosis Factor Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact. <i>Acta Medica Portuguesa</i> , 2019 , 32, 305-312	1.4	2
157	564 Prevalence, Risk Factors, and Global Impact of Musculoskeletal Injuries Among Endoscopists in Portugal. <i>American Journal of Gastroenterology</i> , 2019 , 114, S325-S326	0.7	

156	Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 996-1003	4	11
155	Development and Validation of Risk Matrices Concerning Ulcerative Colitis Outcomes-Bayesian Network Analysis. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 401-409	1.5	7
154	Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 198-208	1.5	57
153	Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. <i>Gut</i> , 2019 , 68, 594-603	19.2	62
152	Concurrent Lip Chancre and Maculopapular Syphilides in a Patient under Anti-TNF β Therapy. <i>Skinmed</i> , 2019 , 17, 343-345	0.2	2
151	Long-Term Safety of In Utero Exposure to Anti-TNF β Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. <i>American Journal of Gastroenterology</i> , 2018 , 113, 396-403	0.7	92
150	Advanced imaging techniques for small bowel Crohn's disease: what does the future hold?. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756283X18757185	4.7	9
149	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 687-694	1.5	7
148	Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 1574	4	15
147	The timing of early therapeutic strategies has a significant impact on Crohn's disease prognosis. <i>Digestive and Liver Disease</i> , 2018 , 50, 462-468	3.3	5
146	P812 Natural disease course of inflammatory bowel disease unclassified in a prospective European population-based inception cohortThe Epi-IBD cohort. <i>Journal of Crohns and Colitis</i> , 2018 , 12, S523-S524 ^{1.5}		
145	Cutaneous Morbidity Among Inflammatory Bowel Disease Patients: A Cohort Study. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 442-451	1.5	10
144	Transmural healing in Crohn's disease: Beyond mural findings. <i>Digestive and Liver Disease</i> , 2018 , 50, 103-104	3.9	4
143	Placebo Effect on the Health-related Quality of Life of Inflammatory Bowel Disease Patients: A Systematic Review With Meta-analysis. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 1232-1244	1.5	12
142	New cross-sectional imaging in IBD. <i>Current Opinion in Gastroenterology</i> , 2018 , 34, 194-207	3	13
141	Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 507-522	6.1	16
140	Fibrosis in Ulcerative Colitis 2018 , 147-157		0
139	The performance of Remicade \square -optimized quantification assays in the assessment of Flixabi \square levels. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756284818796956	4.7	6

138	Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 1297-1303	2.2	21
137	Monitoring Crohn's disease activity: endoscopy, fecal markers and computed tomography enterography. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756284818769075	4.7	9
136	Diagnostic Yield of Next-generation Sequencing in Very Early-onset Inflammatory Bowel Diseases: A Multicentre Study. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 1104-1112	1.5	39
135	Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. <i>Digestive Diseases</i> , 2018 , 36, 346-353	3.5	3
134	The who-when-why triangle of CAM use among Portuguese IBD patients. <i>Digestive and Liver Disease</i> , 2017 , 49, 388-396	3.3	10
133	The effect of PRR ligands on the membrane potential of intestinal epithelial cells. <i>Pharmacological Reports</i> , 2017 , 69, 978-984	3.9	8
132	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 649-670	1.5	837
131	Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1605-1613	4.5	21
130	Looking into Enteric Virome in Patients with IBD: Defining Guilty or Innocence?. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1278-1284	4.5	21
129	Impact of Early Surgery and Immunosuppression on Crohn's Disease Disabling Outcomes. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 289-297	4.5	16
128	Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation. <i>EBioMedicine</i> , 2017 , 21, 123-130	8.8	6
127	Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort-An ECCO-EpiCom Study. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 1213-1222	1.5	18
126	Serial Tuberculosis Screening in Inflammatory Bowel Disease Patients Receiving Anti-TNF β Therapy. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 1223-1229	1.5	9
125	Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients. <i>Digestive and Liver Disease</i> , 2017 , 49, 1289-1297	3.3	15
124	The risk of disabling, surgery and reoperation in Crohn's disease - A decision tree-based approach to prognosis. <i>PLoS ONE</i> , 2017 , 12, e0172165	3.7	11
123	Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays. <i>Therapeutic Advances in Gastroenterology</i> , 2017 , 10, 661-671	4.7	12
122	Clinical performance of an infliximab rapid quantification assay. <i>Therapeutic Advances in Gastroenterology</i> , 2017 , 10, 651-660	4.7	13
121	The NAD ⁺ -dependent deacetylase SIRT2 attenuates oxidative stress and mitochondrial dysfunction and improves insulin sensitivity in hepatocytes. <i>Human Molecular Genetics</i> , 2017 , 26, 4105-4117	5.6	48

120	A Systematic Review and Meta-Analysis of 6-Thioguanine Nucleotide Levels and Clinical Remission in Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 1381-1392	1.5	12
119	Association between Polymorphisms in Antioxidant Genes and Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2017 , 12, e0169102	3.7	16
118	Chronic Granulomatous Disease Mimicking Colonic Crohn's Disease Successfully Treated with Infliximab. <i>ACG Case Reports Journal</i> , 2017 , 4, e46	0.6	1
117	Fecal marker levels as predictors of need for endoscopic balloon dilation in Crohn's disease patients with anastomotic strictures. <i>World Journal of Gastroenterology</i> , 2017 , 23, 6482-6490	5.6	4
116	Endoscopic balloon dilation of Crohn's disease strictures-safety, efficacy and clinical impact. <i>World Journal of Gastroenterology</i> , 2017 , 23, 7397-7406	5.6	11
115	Development and Validation of Risk Matrices for Crohn's Disease Outcomes in Patients Who Underwent Early Therapeutic Interventions. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 445-453	1.5	14
114	Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis-the ACERTIVE study. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 435-444	1.5	18
113	The tuberculin skin test still matters for the screening of latent Tuberculosis infections among Inflammatory Bowel Disease patients. <i>Digestive and Liver Disease</i> , 2016 , 48, 1438-1443	3.3	2
112	"A book should not be judged by its cover": two cases of intestinal adenocarcinoma as the first manifestation of Crohn's disease. <i>International Journal of Colorectal Disease</i> , 2016 , 31, 1061-1062	3	
111	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1426-1432.e1	6.9	28
110	Early surgery in Crohn's disease patients with entero-urinary fistulas: does it change the prognosis?. <i>Scandinavian Journal of Gastroenterology</i> , 2016 , 51, 679-83	2.4	1
109	Refractory monogenic Crohn's disease due to X-linked inhibitor of apoptosis deficiency. <i>International Journal of Colorectal Disease</i> , 2016 , 31, 1235-6	3	4
108	Anti-TNF therapy and radiation exposure in Crohn's disease: chicken or egg?. <i>Scandinavian Journal of Gastroenterology</i> , 2016 , 51, 511-2	2.4	1
107	Reintroduction of Anti-TNF Therapy After (or even During) Anti-TNF-associated Tuberculosis in Immune-mediated Diseases. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 120-1	1.5	8
106	Stool Isolation of Nocardia nova in Two Immunomodulated Patients With Inflammatory Bowel Diseases. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, 92	3	1
105	Amine neurotransmitters, inflammation and epithelial sodium transport. <i>Experimental Physiology</i> , 2016 , 101, 459-64	2.4	6
104	PTU-072 Discontinuation of Infliximab in Patients with Ulcerative Colitis is Associated with Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Gut</i> , 2016 , 65, A88-A89	19.2	
103	Correlation Between Calprotectin and Modified Rutgeerts Score. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 2173-81	4.5	22

102	A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 2289-301	4.5	27
101	Anaemia in Patients with Inflammatory Bowel Disease - A Nationwide Cross-Sectional Study. <i>Digestion</i> , 2016 , 93, 214-20	3.6	17
100	Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 1407-1416	1.5	29
99	European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 873-85	1.5	123
98	Role of epithelial ion transports in inflammatory bowel disease. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 310, G460-76	5.1	15
97	DNA Damage and Oxidative DNA Damage in Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 1316-1323	1.5	35
96	Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 781-794	4.7	12
95	Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 684-92	6.1	40
94	Increased viability but decreased culturability of Mycobacterium avium subsp. paratuberculosis in macrophages from inflammatory bowel disease patients under Infliximab treatment. <i>Medical Microbiology and Immunology</i> , 2015 , 204, 647-56	4	6
93	Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 747-53	1.5	30
92	European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 211-22	1.5	278
91	Ionizing radiation exposure is still increasing in Crohn's disease: Who should be blamed?. <i>Scandinavian Journal of Gastroenterology</i> , 2015 , 50, 1214-25	2.4	11
90	Clinical trials in ulcerative colitis: a historical perspective. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 580-8	1.5	35
89	Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 121-31	4.5	42
88	Short- and long-term regulation of intestinal Na ⁺ /H ⁺ exchange by Toll-like receptors TLR4 and TLR5. <i>American Journal of Physiology - Renal Physiology</i> , 2015 , 309, G703-15	5.1	4
87	Varicella Complicated by Severe Pneumonia and Shock in an Immunosuppressed Crohn's Disease Patient Under Azathioprine and Anti-Tumour Necrosis Factor Alpha. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 1176-8	1.5	3
86	Oxidative Stress and DNA Damage: Implications in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2403-17	4.5	71
85	Assessing overall patient satisfaction in inflammatory bowel disease using structural equation modeling. <i>European Journal of Gastroenterology and Hepatology</i> , 2015 , 27, 941-50	2.2	4

84	Metabolic inflammation in inflammatory bowel disease: crosstalk between adipose tissue and bowel. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 453-67	4.5	53
83	Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases. <i>World Journal of Gastroenterology</i> , 2015 , 21, 7584-8	5.6	65
82	Nocardia infections among immunomodulated inflammatory bowel disease patients: A review. <i>World Journal of Gastroenterology</i> , 2015 , 21, 6491-8	5.6	45
81	Response to Irwin et al. <i>American Journal of Gastroenterology</i> , 2015 , 110, 933-5	0.7	
80	Prevalence of Mycobacterium avium subsp. paratuberculosis and Escherichia coli in blood samples from patients with inflammatory bowel disease. <i>Medical Microbiology and Immunology</i> , 2015 , 204, 681-92	1.4	31
79	Response to Targownik. <i>American Journal of Gastroenterology</i> , 2015 , 110, 349-51	0.7	2
78	The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 107-24	1.5	258
77	European evidence based consensus on surgery for ulcerative colitis. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 4-25	1.5	209
76	The histopathological approach to inflammatory bowel disease: a practice guide. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 464, 511-27	5.1	58
75	Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 443-68	1.5	633
74	Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe--an ECCO-EpiCom study. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 607-16	1.5	58
73	Disseminated cutaneous herpes simplex infection in a patient with Crohn's disease under azathioprine and steroids: First case report and literature review. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 326-30	1.5	11
72	Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 1506-15	1.5	66
71	Imaging techniques in IBD and their role in follow-up and surveillance. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 722-36	24.2	29
70	Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1026-36	0.7	63
69	Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). <i>Journal of Crohns and Colitis</i> , 2014 , 8, 31-44	1.5	111
68	High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 129-36	1.5	56
67	Listeria monocytogenes bacteremia and CMV colitis in a patient with Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 254-5	1.5	2

66	Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 1166-78	1.5	48
65	Health care and patients' education in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 811-8	1.5	14
64	Mimicry between intestinal Behçet's disease and inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 714-5	1.5	4
63	Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 617-25	1.5	11
62	Infliximab therapy increases the frequency of circulating CD16(+) monocytes and modifies macrophage cytokine response to bacterial infection. <i>Clinical and Experimental Immunology</i> , 2014 , 177, 703-11	6.2	19
61	Immunisations in Crohn's disease: who? why? what? when?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2014 , 28, 485-96	2.5	7
60	C-reactive protein in Crohn's disease: how informative is it?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014 , 8, 393-408	4.2	18
59	East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. <i>Gut</i> , 2014 , 63, 588-97	19.2	246
58	Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 36-46	4.5	65
57	Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with inflammatory bowel disease--an ECCO-EpiCom study. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 1030-42	1.5	36
56	Earlier need of infliximab intensification in ulcerative colitis than in Crohn's disease. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 1331-2	1.5	3
55	Are we on our way to change our mode of thinking and treating inflammatory bowel disease patients?. <i>Annals of Gastroenterology</i> , 2014 , 27, 424-426	2.2	
54	Venous thrombosis and prothrombotic factors in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 4857-72	5.6	66
53	Phenotype-genotype profiles in Crohn's disease predicted by genetic markers in autophagy-related genes (GOIA study II). <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 230-9	4.5	35
52	Listeria infection in patients on anti-TNF treatment: report of two cases and review of the literature. <i>Journal of Crohns and Colitis</i> , 2013 , 7, 175-82	1.5	37
51	European consensus on the histopathology of inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , 2013 , 7, 827-51	1.5	376
50	Tuberculosis in anti-TNF-treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. <i>Journal of Crohns and Colitis</i> , 2013 , 7, e486-92	1.5	53
49	Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. <i>Journal of Crohns and Colitis</i> , 2013 , 7, 556-85	1.5	438

48	Short- and long-term regulation of intestinal Na ⁺ /H ⁺ exchange activity associated with TLR2 receptor activation is independent of nuclear factor- κ B signaling. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013 , 346, 453-64	4.7	5
47	Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 1456-63	2.2	41
46	Epstein-Barr virus in inflammatory bowel disease-correlation with different therapeutic regimens. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 1710-6	4.5	32
45	Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 2098-110	4.5	82
44	Clinical prognostic factors for disabling Crohn's disease: a systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2013 , 19, 3866-71	5.6	27
43	Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 573-83	4.5	92
42	Oral squamous cell carcinoma in a Crohn's disease patient taking azathioprine: case report and review of the literature. <i>Journal of Crohns and Colitis</i> , 2012 , 6, 792-5	1.5	14
41	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. <i>Journal of Crohns and Colitis</i> , 2012 , 6, 965-90	1.5	592
40	Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature. <i>Dermatology</i> , 2012 , 225, 163-7	4.4	31
39	Dysplasia surveillance in an ulcerative colitis patient: successful detection with narrow band imaging and magnification. <i>Journal of Crohns and Colitis</i> , 2011 , 5, 54-6	1.5	2
38	Liver abscess of the caudate lobe due to Staphylococcus aureus in an ulcerative colitis patient: First case report. <i>Journal of Crohns and Colitis</i> , 2011 , 5, 360-3	1.5	7
37	Construction and validation of a web-based epidemiological database for inflammatory bowel diseases in Europe An EpiCom study. <i>Journal of Crohns and Colitis</i> , 2011 , 5, 342-9	1.5	28
36	Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , 2011 , 5, 477-83	1.5	247
35	Macrophages from IBD patients exhibit defective tumour necrosis factor- β secretion but otherwise normal or augmented pro-inflammatory responses to infection. <i>Immunobiology</i> , 2011 , 216, 961-70	3.4	31
34	Metastatic cutaneous Crohn's disease of the face: a case report and review of the literature. <i>European Journal of Gastroenterology and Hepatology</i> , 2011 , 23, 954-6	2.2	15
33	How to manage pouchitis in ulcerative colitis?. <i>Current Drug Targets</i> , 2011 , 12, 1454-61	3	7
32	Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. <i>BioDrugs</i> , 2010 , 24 Suppl 1, 3-14	7.9	71
31	Severe gram positive bacterial infection in an ulcerative colitis patient treated with Infliximab. <i>Journal of Crohns and Colitis</i> , 2010 , 4, 110-3	1.5	7

30	Clinical practice in Crohn's disease in bordering regions of two countries: different medical options, distinct surgical events. <i>Journal of Crohns and Colitis</i> , 2010 , 4, 301-11	1.5	6
29	Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor therapies. Foreword. <i>BioDrugs</i> , 2010 , 24 Suppl 1, 1-2	7.9	2
28	Ulcerative colitis in a Southern European country: a national perspective. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 822-9	4.5	10
27	Ulcerative colitis in northern Portugal and Galicia in Spain. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1227-38	4.5	22
26	Case series: ulcerative colitis, multiple sclerosis, and interferon-beta 1a. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 2001-3	4.5	12
25	Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach. <i>Pharmacoepidemiology and Drug Safety</i> , 2010 , 19, 499-510	2.6	18
24	Crohn's disease in a southern European country: Montreal classification and clinical activity. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1343-50	4.5	18
23	Inflammatory bowel disease: a patient's and caregiver's perspective. <i>Digestive Diseases and Sciences</i> , 2009 , 54, 2671-9	4	28
22	Systematic review on drug and diet-induced endoscopic remission in Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2009 , 21, 491-503	2.2	6
21	Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 723-5	4.5	38
20	Infliximab dose intensification by shortening infusion intervals. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 432-4	4.5	8
19	Short-term effect on intestinal epithelial Na(+)/H(+) exchanger by Gi(alpha1,2)-coupled 5-HT(1A) and G(q/11)-coupled 5-HT(2) receptors. <i>Life Sciences</i> , 2007 , 81, 560-9	6.8	5
18	Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 1087-9	4.5	21
17	Intestinal 5-hydroxytryptamine and mast cell infiltration in rat experimental colitis. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 495-501	4	14
16	Dopamine D2 receptor polymorphisms in inflammatory bowel disease and the refractory response to treatment. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 2039-44	4	30
15	Regional intestinal adaptations in Na ⁺ ,K ⁺ -ATPase in experimental colitis and the contrasting effects of interferon-gamma. <i>Acta Physiologica Scandinavica</i> , 2005 , 183, 191-9		9
14	Signaling of short- and long-term regulation of intestinal epithelial type 1 Na ⁺ /H ⁺ exchanger by interferon-gamma. <i>British Journal of Pharmacology</i> , 2005 , 145, 93-103	8.6	19
13	Unusual presentation of tuberculosis after infliximab therapy. <i>Inflammatory Bowel Diseases</i> , 2005 , 11, 82-4	4.5	4

12	Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis?. <i>Inflammatory Bowel Diseases</i> , 2005 , 11, 88-90	4.5	3
11	Interferon-gamma-induced STAT1-mediated membrane retention of NHE1 and associated proteins ezrin, radixin and moesin in HT-29 cells. <i>Biochemical Pharmacology</i> , 2005 , 70, 1312-9	6	14
10	Gingival hyperplasia as a first manifestation of Crohn's disease. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 1946-9	4	7
9	Colon stenosis in a patient with ulcerative colitis as a manifestation of mixed müllerian tumor of the peritoneum. <i>Scandinavian Journal of Gastroenterology</i> , 2005 , 40, 1251-4	2.4	2
8	Decreased availability of intestinal dopamine in transmural colitis may relate to inhibitory effects of interferon-gamma upon L-DOPA uptake. <i>Acta Physiologica Scandinavica</i> , 2004 , 180, 379-86		34
7	Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 2004 , 49, 1265-74	4	39
6	Intestinal Na ⁺ -K ⁺ -ATPase activity and molecular events downstream of interferon-gamma receptor stimulation. <i>British Journal of Pharmacology</i> , 2004 , 142, 1281-92	8.6	14
5	High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2003 , 15, 1157-63	2.2	38
4	Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 2002 , 47, 216-24	4	139
3	Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. <i>Journal of Clinical Gastroenterology</i> , 1996 , 23, 29-34	3	273
2	Severe Hemorrhagic Enteropathy Secondary to Salmonella typhi. <i>GE Portuguese Journal of Gastroenterology</i> , 1-3	1.1	
1	Exploring the Ways of "The Great Imitator" A Case Report of Syphilitic Hepatitis. <i>GE Portuguese Journal of Gastroenterology</i> , 1-4	1.1	